Actavis buys Amide Pharmaceuticals
DEALS |
|||
WHO |
WITH |
WHAT |
SCOOP |
Bionomics |
Iliad Chemicals |
$9M buyout |
The deal is intended to help beef up Bionomics' pipeline toward its goal of having two Phase II products and five preclinical programs by 2008. |
Actavis |
Amide Pharmaceuticals |
$500M buyout |
The buyout gives Actavis a much bigger beachhead in the American generics market, making it easier to sell generic drugs and introduce new pharmaceuticals. |
Cephalon |
Salmedix |
$160M buyout |
Researchers at Salmedix have been testing Treanda as both a treatment for non-Hodgkin's lymphoma for patients who have not responded to Rituxan and a complement to Rituxan. |
Invitrogen |
Caltag Laboratories |
$20M buyout |
The deal adds Caltag's library of antibodies to Invitrogen's rapidly expanding stockpile. |
BioXell |
Merck |
$150M drug development pact |
Merck has agreed to pay up to that amount to develop the company's lead product, TREM-1, which targets a receptor on specific immune cells. |
Lexicon Genetics |
Organon Labs |
Drug collaboration |
The research work will concentrate on 300 genes that encode therapeutic antibodies and proteins. |